Copyright: ©Author(s) 2026.
World J Hematol. Nov 20, 2026; 12(3): 126171
Published online Nov 20, 2026. doi: 10.5315/wjh.126171
Published online Nov 20, 2026. doi: 10.5315/wjh.126171
Table 1 Randomized controlled trials and pooled analysis of viscoelastic testing-guided transfusion in cirrhosis
| Ref. | Design and sample size | Clinical setting | Assay | Transfusion outcome | Bleeding and mortality outcome |
| Rout et al[13] | RCT, 30 vs 30, India | Acute variceal bleeding | TEG | 4 patients (13.3%) vs all patients (100%) transfused, P < 0.001 | Rebleeding at 5 days 3.3% vs 13.3%, P = 0.167; rebleeding at 42 days 10.0% vs 36.7%, P = 0.012; 6-week mortality 13.3% vs 26.7%, P = 0.176 |
| Kumar M et al[14] | RCT, 49 vs 47, India | Nonvariceal upper GI bleeding in advanced cirrhosis | TEG | All three components (plasma, platelets, and cryoprecipitate) given to 26.5% vs 87.2%, P < 0.001 | Failure to control bleeding, rebleeding, and mortality similar in both arms |
| Vuyyuru et al[15] | RCT, 29 vs 29, India | High-risk invasive liver-related procedures | TEG | 9 patients (31%) vs all patients (100%) transfused | No procedure-related bleeding through 5 days in either arm |
| Biswas et al[16] | RCT, three arms of 29, India | Severe thrombocytopenia before invasive procedures | TEG | Platelets: 4/29 (13.8%) with TEG, 29/29 (100%) with standard care, and 4/29 (13.8%) on demand; P < 0.001 for TEG vs standard care | Minor bleeding in 3 (10%) with TEG vs 1 (3.4%) in each comparator arm, P = 0.43; no bleeding-related death |
| Kumar R et al[17] | RCT, 20 vs 20, Singapore | Elective procedures, predominantly low to intermediate risk | ROTEM | 40% vs 100% transfused, P < 0.001; less plasma, P < 0.001, and fewer platelets, P = 0.046 | No clinically significant bleeding; 30-day and 90-day mortality did not differ significantly |
| Hartmann et al[4] | Meta-analysis of 5 earlier RCTs (302 patients) | Cirrhosis, including liver transplantation | TEG | Platelet use RR 0.17, 95%CI 0.03-0.90, P = 0.04 | 7-day mortality RR 0.52, 95%CI 0.30-0.91, P = 0.02 |
- Citation: Salman A. Artificial intelligence and the rebalanced hemostasis of chronic liver disease: From viscoelastic testing to digital twins. World J Hematol 2026; 12(3): 126171
- URL: https://www.wjgnet.com/2218-6204/full/v12/i3/126171.htm
- DOI: https://dx.doi.org/10.5315/wjh.126171